Cancer NetworkOriginal article
<![CDATA[Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis]]>
Phase 2positiveselcodebartPositive
AI Analysis
Summary
Selcodebart demonstrated a 55% major response rate in the phase 2 RALLY-MF study among non-transfusion-dependent myelofibrosis patients with anemia. The positive data supports further clinical development of the drug candidate.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
55% major response rate among evaluable non-transfusion-dependent patients
Importance:6/10
Sentiment:
0.70
Phase 2HematologyMyelofibrosisClinical Trial Data
Read the original article
Published by Cancer Network on October 9, 2026 5:00 PM